A phase 2 expansion study of ARV-766, a PROTAC androgen receptor degrader, in metastatic castration-resistant prostate cancer

Daniel P Petrylak¹, Tyler F Stewart², Xin Gao³, Elmer Berghorn⁴, Haolan Lu⁴, Edward Chan⁴, Richard Gedrich⁴, Joshua M Lang⁵, and Meredith McKean⁶

¹Smilow Cancer Center, Yale School of Medicine, New Haven, CT; ²UC San Diego Health, La Jolla, CA; ³Massachusetts General Hospital, Boston, MA; ⁴Arvinas Operations, Inc., New Haven, CT; ⁵Carbone Cancer Center, University of Wisconsin–Madison, Madison, WI; ⁶Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN

Objective

 This phase 2 expansion cohort will evaluate the clinical activity and safety of ARV-766 in men with metastatic castration-resistant prostate cancer (mCRPC) who have experienced disease progression on prior novel hormonal agent (NHA) therapy

References

- 1. Boudadi K, et al. Clin Med Insights Oncol. 2016;10(suppl 1):1-9.
- 2. Békés M, et al. *Nat Rev Drug Discov*. 2022;21(3):181-200.
- 3. Nalawansha DA, et al. *Cell Chem Biol*. 2020;27(8):998-1014.

Acknowledgments

We thank the patients participating in this study and their caregivers, and the investigators, researchers, and coordinators contributing to this study. This study is sponsored by Arvinas Androgen Receptor, Inc. Medical writing support was provided by Jessica Olive, PhD, of Apollo Medical Communications and funded by Arvinas Operations, Inc.



Plain Language Summary
Please scan this Quick Response
(QR) code with your smartphone
app to view a plain language Please scan this Quick Response app to view a plain language summary of the poster.


Contact

Daniel P Petrylak, MD; daniel.petrylak@yale.edu

Background and Rationale

- Patients with mCRPC inevitably develop resistance to available therapies and lack curative options¹
- New therapies that target different pathways, have novel mechanisms of action, and/or address mechanisms of resistance for patients who have progressed on current NHAs (eg, abiraterone, enzalutamide, darolutamide, or apalutamide) are needed to improve outcomes in patients with mCRPC1
- The PROteolysis TArgeting Chimera (PROTAC) androgen receptor (AR) degrader ARV-766 is a heterobifunctional small molecule consisting of an AR-binding domain joined by a linker to an E3 ubiquitin ligase-binding domain
- ARV-766 creates a trimer complex with AR and an E3 ubiquitin ligase to directly trigger ubiquitination and subsequent rapid and complete degradation of AR by the proteasome (**Figure 1**)²


- ARV-766 can block AR stimulation by androgens through elimination of AR rather than competitive inhibition of the AR binding site (ie, enzalutamide) or inhibiting androgen synthesis (ie, abiraterone)^{1,3}
- ARV-766 is a novel, potent, orally administered PROTAC AR degrader
 - ARV-766 degrades not only wild-type AR, but also clinically relevant AR ligand-binding domain mutants, including the most prevalent AR L702H, H875Y, and T878A mutations (data on file)
- A phase 1 dose escalation portion of a phase 1/2 trial (NCT05067140) was conducted to determine the safety and tolerability of ARV-766 in patients with mCRPC who had progressed on ≥2 prior approved systemic treatments, including ≥1 NHA, and to select the doses evaluated in the phase 2 expansion cohort



^aGeneral PROTAC protein degrader is shown AR=androgen receptor; PROTAC=PROteolysis TArgeting Chimera

Study Design

• In this open-label, multicenter, phase 2 expansion cohort, patients will be randomized to receive oral ARV-766 daily, either 100 mg or 300 mg, in 28-day cycles (Figure 2)



- Eligible patients have mCRPC, prior NHA therapy, and ongoing androgen deprivation therapy (**Table 1**)
- Objectives and endpoints are shown in Table 2
- Patients will be enrolled in multiple centers across the United States
- Enrollment is ongoing

Table 1: Key eligibility criteria

Inclusion criteria

- Men aged ≥18 years
- Histological, pathological, or cytological confirmed diagnosis of adenocarcinoma of the prostate
- Progressive mCRPC
- 1–3 prior NHAs (eg, enzalutamide or abiraterone)
- ≤2 prior chemotherapy regimens
- Ongoing ADT with a gonadotropin-releasing hormone analog or inhibitor, or orchiectomy (surgical or medical castration)
- ECOG performance status of 0 or 1

- **Exclusion criteria**
- Symptomatic brain metastases requiring steroids above physiologic replacement doses
- Active inflammatory gastrointestinal disease, chronic diarrhea, known diverticular disease, or previous gastric resection or lap band surgery
- Radiation therapy ≤4 weeks from start of treatment or prior irradiation to >25% of the bone marrow
- Treatment with investigational drug(s) ≤4 weeks prior to anticipated first dose of study drug
- Systemic anticancer therapy ≤2 weeks prior to first dose of study drug (except agents to maintain castrate status)
- ≤6 weeks for bicalutamide, mitomycin C, or nitrosoureas
- ≤4 weeks for abiraterone

ADT=androgen deprivation therapy; ECOG=Eastern Cooperative Oncology Group; mCRPC=metastatic castration-resistant prostate cancer; NHA=novel hormonal agent

Table 2: Outcome measures^a

| Primary objective | Endpoints |
|--|------------------------|
| Evaluate the antitumor activity of ARV-766 | ORR (RECIST) |
| | PSA ₃₀ rate |
| | PSA ₅₀ rate |
| Secondary objective | Endpoints |

Secondary objective

Evaluate the safety and tolerability of ARV-766

Frequency and severity of adverse events and laboratory abnormalities

^aNot all secondary objectives and endpoints are shown ORR=overall response rate; PSA₃₀=prostate-specific antigen decline of >30%; PSA₅₀=prostate-specific antigen decline of >50%; RECIST=Response Evaluation Criteria in Solid Tumors